Most published CB2 imaging studies describe substantial binding of radiotracer to the spleen and discuss the ability of the radioligands to cross the blood-brain barrier as well as aspects of non-specific binding in control rather than models relevant to AD. The gene discussed is CNR2; the disease is Alzheimer disease.